Biomarin Pharmaceutical (BMRN) Cash from Investing Activities (QoQ) (2009 - 2026)
Biomarin Pharmaceutical (BMRN) Cash from Investing Activities (QoQ) (2009 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Biomarin Pharmaceutical | 11.65 Bn | 9.42 Bn | 571.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1,809.18% |
| Dec 31, 2025 | 87.17% |
| Sep 30, 2025 | -2,528.36% |
| Jun 30, 2025 | 55.41% |
| Mar 31, 2025 | -136.96% |
| Dec 31, 2024 | 572.88% |
| Sep 30, 2024 | -117.86% |
| Jun 30, 2024 | 735.57% |
| Mar 31, 2024 | 78.09% |
| Dec 31, 2023 | -41.84% |
| Sep 30, 2023 | -255.09% |
| Jun 30, 2023 | 198.39% |
| Mar 31, 2023 | 45.14% |
| Dec 31, 2022 | -133.78% |
| Sep 30, 2022 | 21.20% |
| Jun 30, 2022 | -133.83% |
| Mar 31, 2022 | 258.39% |
| Dec 31, 2021 | 53.76% |
| Sep 30, 2021 | 0.34% |
| Jun 30, 2021 | -69.88% |